ABBV Jun 2025 175.000 call
| Previous Close | 7.39 |
| Open | 7.55 |
| Bid | 7.90 |
| Ask | 8.45 |
| Strike | 175.00 |
| Expire Date | 2025-06-20 |
| Day's Range | 7.39 - 7.55 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 532 |
ZacksAbbVie (ABBV) Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU
AbbVie (ABBV) announces that the EMA's CHMP issued a positive opinion on its regulatory filing seeking label expansion for the immunology drug, Skyrizi, to treat UC.
PR NewswireAbbVie to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024. Robert A. Michael, president and chief operating officer, Scott T. Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, M.D., senior vice president, chief medical officer, global therapeutics, will present at 9:00 a.m. Central time.
ZacksAbbVie (ABBV) Soars 3.2%: Is Further Upside Left in the Stock?
AbbVie (ABBV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
